Skip to content

Effect of pain relieving action of piroxicam in patients with osteoarthritis of knee due to minor modification in gene degrading piroxicam

Influence of CYP2C9 gene polymorphisms on the analgesic effect of piroxicam in patients with osteoarthritis of knee

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013673
Enrollment
100
Registered
2018-05-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee Health Condition 2: null- Osteoarthritis of knee

Interventions

Intervention1: Piroxicam: Tablet piroxicam 20mg orally twice daily after food for 6 weeks Control Intervention1: Not applicable: Not applicable

Sponsors

Sri Devaraj Urs Academy of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either gender, aged between 40-70years 2.Body mass index (BMI) of 25-30 3.Patients with symptomatic idiopathic OA 4.Knee osteoarthritis of mild to moderate type 5.Radiological evidence of OA of involved joint 6.Morning stiffness of less than 30 minutes duration with crepitus on motion 7.Patients who were on NSAIDs including piroxicam and should have discontinued the drug for a period of two weeks before recruitment

Exclusion criteria

Exclusion criteria: 1.Patients with history of surgery or acute trauma to the knee joint in the past 6months 2.Patients with history of peptic ulcer, gastrointestinal bleeding, psychiatric illness and bronchial asthma 3.Patients with history of acute inflammatory arthritis, pseudo gout or severe osteoporosis 4.Patients with history of allergy to study drug 5.Patients with deranged hepatic and renal parameters 6.Pregnant and lactating women 7.Patients who use other measures for pain relief like massage, acupuncture, hydrotherapy, homeopathy, chiropractic manipulation, transcutaneous electrical nerve stimulation, use of knee braces, shoe wedges, application of creams containing capsaicin, self medication with analgesics and nutritional supplements like glucosamine and chondroitin sulfate during the past 4 weeks and study period. 8.Patients with uncontrolled diabetes mellitus and hypertension

Design outcomes

Primary

MeasureTime frame
Correlate the CYP2C9 gene polymorphisms with reduction in VAS (Visual Analogue Scale),WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)score and Patientâ??s satisfaction score Timepoint: 24 months

Secondary

MeasureTime frame
VAS, WOMAC, Patients satisfaction score, Adverse effects using WHO causality assessment scaleTimepoint: 2, 4, 6 weeks, 3rd month, 6th month and 1 year after starting the drug

Countries

India

Contacts

Public ContactBhuvana K

Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research

drbhuvanak2010@gmail.com9900383738

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026